DEF: Artivion Sets 2026 Annual Meeting, Details Executive Pay & Strong 2025 Performance

Artivion, Inc. announced its virtual 2026 Annual Meeting of Stockholders, revealing robust 2025 financial performance with 13.2% constant currency revenue growth and 28.6% adjusted EBITDA growth, alongside executive compensation details and governance updates.

Summary

• Artivion will hold its Annual Meeting of Stockholders virtually on May 12, 2026, at 9:00 a.m. ET, with a record date of March 16, 2026.
• Stockholders will vote on the election of nine director nominees, an advisory resolution on executive officer compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.
• The company achieved 13.2% constant currency revenue growth and 28.6% constant currency adjusted EBITDA growth in 2025, resulting in adjusted EBITDA of $89.6 million.
• Executive compensation for 2025 included base salary increases of 3.0-8.4% and incentive plan payouts of 118.7% of target, reflecting strong company performance.
• Lance A. Berry was promoted to Executive Vice President, Chief Operating Officer, Chief Financial Officer, and Treasurer on August 11, 2025, leading to an 8.0% base salary increase and a prorated bonus target increase to 70%.
• The Board of Directors recommends voting FOR all proposals.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive filing, reflecting robust financial performance that exceeded targets, high shareholder approval for compensation, and strategic progress in product development and international expansion. The detailed governance and compensation disclosures are transparent and align with best practices.

Positives

• Strong 2025 financial performance with 13.2% constant currency revenue growth.
• Significant 2025 constant currency adjusted EBITDA growth of 28.6%, reaching $89.6 million.
• Executive incentive plans paid out at 118.7% of target, indicating successful achievement of performance goals.
• High stockholder support for 2024 executive compensation, with 97% approval in the Say on Pay vote.
• Successful use of virtual-only format for prior annual meetings.
• All non-employee directors are deemed independent under NYSE Listing Standards.
• All current non-employee directors satisfy the stock ownership requirement of five times their annual Board service retainer.
• Made three important regulatory filings with the FDA to bring aortic stent graft products to the U.S. market.
• Experienced rapid growth in international markets, particularly Asia Pacific and Latin America.

Risks

• Future events may not occur as and when expected, and are subject to a number of risks, uncertainties, estimates, and assumptions.
• Management's ability to attain certain performance targets is subject to risks affecting the economy generally and other factors that are beyond the company's control.
• Regulatory and clinical challenges are associated with the transition to the MDR in Europe and the introduction of the company's aortic stent graft products into the U.S. market.

Future Outlook

The company expects to publish its updated annual Corporate Responsibility Report in the second quarter of 2026, highlighting sustainability initiatives, goals, and efforts. Management's ability to achieve certain performance targets is subject to general economic risks and other uncontrollable factors. The company intends to continue structuring executive compensation arrangements to comply with Section 409A of the Code.

Management Comments

• "On behalf of the Board of Directors, we invite you to attend the Annual Meeting of Stockholders of Artivion, Inc. on May 12, 2026, at 9:00 a.m., ET."
• "Given our successful use of the virtual-only format at our prior annual meetings, we have again adopted a virtual-only format for our Annual Meeting this year."
• "After this year's Annual Meeting, we intend to again evaluate the best method for holding our annual stockholder meetings going forward."
• "We believe that the form and amount of compensation we provide to our current Named Executive Officers appropriately reflects their extensive management experience, continued high performance, and exceptional service to Artivion and our stockholders."
• "We believe in a corporate governance structure that is responsive to stockholder concerns. We view this vote as a meaningful opportunity to gauge stockholder approval of our executive officer compensation policies."
• "The Committee believes it has developed a compensation program that ensures that the interests of the Company's executive officers, including its NEOs, are aligned with those of its stockholders by strongly linking executive officer compensation with Company and personal performance at levels such that executive officers are incented to drive long-term value creation, especially given the Company's growth objectives in the coming years."

Industry Context

StockSavvy.ai notes that Artivion's strong 2025 financial performance, particularly in constant currency revenue and adjusted EBITDA growth, positions it favorably within the medical device industry. The company's focus on bringing aortic stent graft products to the U.S. market via FDA filings and its rapid international expansion in Asia Pacific and Latin America indicate a strategic drive for market share and diversification, aligning with broader industry trends of global growth and innovation in specialized medical technologies. The ongoing transition to MDR in Europe also reflects the evolving regulatory landscape impacting medical device manufacturers.

Comparison to Industry Standards

• Artivion's 2025 constant currency revenue growth of 13.2% and adjusted EBITDA growth of 28.6% are strong indicators of performance, especially when compared to its 2024 compensation peer group which had a median revenue of $412.2 million.
• The company's executive compensation structure, which uses a mix of RSUs and PSUs and foregoes options, is noted as being "more in-line with current market trends and the Company's proxy peers," suggesting alignment with modern compensation practices in the medical device sector.
• The 97% stockholder approval for the 2024 Say on Pay vote indicates strong investor confidence in Artivion's executive compensation practices, which is a positive signal compared to companies facing significant shareholder dissent on executive pay.
• The company's peer group for 2024 included companies like Tandem Diabetes Care, Orthofix Medical, and Avanos Medical, with Artivion's 2025 adjusted revenue of $443.6 million exceeding the peer group's median revenue of $412.2 million, suggesting competitive or superior growth relative to its direct comparables.
• The strategic expansion into Asia Pacific and Latin American markets, alongside efforts to introduce aortic stent graft products in the U.S., demonstrates a global growth strategy comparable to leading medical device companies seeking to diversify revenue streams and penetrate high-growth regions.

Management Changes

Corporate Governance

Related Party Transactions

• The Audit Committee oversees and must review and approve all significant related-party transactions.
• The company's policy requires Audit Committee review and approval for any transaction exceeding $50,000 annually involving related parties, including non-employee directors, executive officers, beneficial owners of more than 5% of stock, their immediate family members, or entities they control or are employed by.

Stakeholder Impact

• Shareholders: Direct impact through voting on directors, executive compensation, and auditor ratification. Benefit from strong financial performance (13.2% revenue growth, 28.6% adjusted EBITDA growth) and alignment of executive compensation with performance. Potential for long-term value creation through strategic initiatives.
• Employees: Executive officers received base salary increases (3.0-8.4%) and incentive payouts (118.7% of target). Benefit from a compensation philosophy designed to attract, retain, motivate, and reward talent. The company's Corporate Responsibility Report highlights a commitment to a welcoming and empowering workplace.
• Customers: Benefit from the company's focus on bringing leading-edge aortic technologies to market (FDA filings) and rapid growth in international markets.
• Regulatory Authorities: The Innovation and Healthcare Compliance Committee oversees the company's compliance with healthcare laws and regulations, quality systems, GDPR, and FCPA.
• Management: Compensation is tied to company performance, with significant long-term incentives. Promotion opportunities, such as Lance A. Berry's appointment to COO, demonstrate career progression within the company.

Next Steps

• Hold the Annual Meeting of Stockholders on May 12, 2026.
• Elect nine director nominees.
• Conduct an advisory vote on executive officer compensation.
• Ratify Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.
• Evaluate the best method for holding annual stockholder meetings going forward after the 2026 Annual Meeting.
• Publish the updated annual Corporate Responsibility Report in the second quarter of 2026.
• Continue efforts related to Artivion's internal controls over financial reporting and management's preparations for evaluation.
• Continue to bring aortic stent graft products to the U.S. market following FDA filings.

Key Dates

Recommendation

The filing reveals Artivion's exceptional financial performance in 2025, with constant currency revenue growth of 13.2% and adjusted EBITDA growth of 28.6%, both exceeding targets. This strong operational execution, coupled with strategic progress in FDA filings for aortic stent grafts and rapid international expansion, indicates robust underlying business momentum. The high shareholder approval for executive compensation further signals confidence in management's ability to deliver value. The company's commitment to strong corporate governance, including independent board oversight and rigorous risk management, provides a solid foundation. These factors collectively suggest a company poised for continued growth and value creation, making it a compelling "strong buy" for seasoned investors.

Keywords

Artivion, Proxy Statement, Executive Compensation, Corporate Governance, SEC Filing, Annual Meeting, Director Election, Financial Performance, Revenue Growth, EBITDA Growth, Medical Device Industry, Aortic Stent Grafts, Stockholder Vote, Risk Oversight, Sustainability, FDA Filings, International Markets